Navigation Links
BSP Signs Agreement With CMP Trading for Distribution of HyperQ(TM) Stress System, for Early Detection of Ischemic Heart Disease, in South Korea
Date:11/10/2008

CMP Will Purchase at Least 227 HyperQ(TM) Systems During the Term of the

Agreement

TEL AVIV, Israel, November 10 /PRNewswire-FirstCall/ -- BSP (Biological Signal Processing Ltd.) (http://www.bsp.co.il/), an Israeli company that develops and markets innovative systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease (IHD), announced that it has signed an exclusive distribution agreement with CMP Trading Co., Ltd to distribute HyperQ(TM) Stress System in South Korea.

CMP has undertaken to purchase at least 227 HyperQ(TM) systems through the end of 2011. The number of systems may change subject to the date of receipt of regulatory approval from the Korean Food and Drug Administration, an essential step towards the marketing and use of the system in Korea. BSP estimates that the price per system to CMP will vary from about US$ 15,000 to roughly US$ 20,000, dependent on the system configuration. Accordingly, the total revenues resulting from this agreement are expected to be a minimum of US$ 3,400,000.

Mr. Chan Min Park, President of CMP Trading said, "We are extremely encouraged by the very positive response to the HyperQ technology from medical centers. We believe that BSP's product can change the way ischemic heart diseases are being diagnosed."

"This second distribution agreement consolidates BSP's position in the Asia-Pacific markets. We view Korea as one of the most receptive countries to innovative technologies," said Dr. Amir Beker, BSP's founder and CEO.

Dr. Beker adds, "We are grateful for the ongoing vote of confidence in our HyperQ technology by leading physicians in Asia and the United States. We plan to continue with the installment of our HyperQ system into top medical centers."

This week, BSP is introducing its new version of the HyperQ(TM) System at the 2008 conference of the American Heart Association in New Orleans.

BSP - background

BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP was founded in 2000 by Dr. Amir Beker and Mr. Ariel Landau and has completed a successful IPO in mid-2006 and its shares are traded on the Tel Aviv Stock Exchange.

Contacts:

Dr. Amir Beker, CEO

Dr. Neri Malka, Head of Clinical Marketing

Tel: +1-888-669-1671; +972-3-647-4840


'/>"/>
SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
2. Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan
3. Oridion Signs Agreement With Major US Health Plan Provider for Microstream(R) Capnography
4. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
5. STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine
6. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
7. Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
8. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
9. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
10. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
11. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):